Literature DB >> 11040852

Infection and immunity in chronic lymphocytic leukemia.

S Tsiodras1, G Samonis, M J Keating, D P Kontoyiannis.   

Abstract

Patients having chronic lymphocytic leukemia (CLL) are at increased risk for infectious morbidity and mortality. The predisposition to infections in CLL patients has many components, including both immunodeficiency related to the leukemia itself (humoral and cellular immune dysfunction) and the results of cumulative immunosuppression related to CLL treatment. The risk of infectious complications increases with the duration of CLL, reflecting the natural history of the disease and the cumulative immunosuppression related to its treatment. Hence, in early, untreated CLL, the infectious risk is mainly related to hypogammaglobulinemia, and infections by encapsulated bacteria are common. However, in patients having advanced CLL, particularly those who receive the newer purine analogues, neutropenia and defects in cell-mediated immunity appear to be the major predisposing factors. An expanded spectrum of pathogens, including opportunistic fungi, Pneumocystis carinii, Listeria monocytogenes, mycobacteria, and herpesviruses, are seen in that setting. The changing spectrum of infections in this latter group of patients mandates a newer approach to prophylaxis and therapy.

Entities:  

Mesh:

Year:  2000        PMID: 11040852     DOI: 10.4065/75.10.1039

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  30 in total

Review 1.  Granulomatous reactions cause symptoms or clinically imitate treatment resistance in small lymphocytic lymphoma/chronic lymphocytic leukaemia more frequently than in other non-Hodgkin lymphomas.

Authors:  A Brunner; J Kantner; A Tzankov
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

2.  Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia.

Authors:  Dimitrios P Kontoyiannis; Sarah P Georgiadou; William G Wierda; Susan Wright; Nathaniel D Albert; Alessandra Ferrajoli; Michael Keating; Russell E Lewis
Journal:  Leuk Lymphoma       Date:  2013-02-20

3.  Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infections.

Authors:  Nirojah Subramaniam; Jenny Bottek; Stephanie Thiebes; Kristina Zec; Matthias Kudla; Camille Soun; Elena de Dios Panal; Julia K Lill; Aaron Pfennig; Ralf Herrmann; Kirsten Bruderek; Sven Rahmann; Sven Brandau; Patricia Johansson; Hans Christian Reinhardt; Jan Dürig; Martina Seiffert; Thilo Bracht; Barbara Sitek; Daniel Robert Engel
Journal:  Blood Adv       Date:  2021-03-09

4.  Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.

Authors:  Priscilla Do; Kyle A Beckwith; Carolyn Cheney; Minh Tran; Larry Beaver; Brittany G Griffin; Xiaokui Mo; Yang Liu; Rosa Lapalombella; Erin Hertlein; Natarajan Muthusamy; John C Byrd
Journal:  J Immunol       Date:  2019-03-25       Impact factor: 5.422

Review 5.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 6.  Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.

Authors:  Ben Kennedy; Peter Hillmen
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

7.  Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.

Authors:  Paolo Strati; Joon H Uhm; Timothy J Kaufmann; Chadi Nabhan; Sameer A Parikh; Curtis A Hanson; Kari G Chaffee; Timothy G Call; Tait D Shanafelt
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

Review 8.  Targeting inflammatory pathways in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; Michael J Keating; Zeev Estrov
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-12       Impact factor: 6.312

9.  Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia.

Authors:  Lesley A Anderson; Ola Landgren; Eric A Engels
Journal:  Br J Haematol       Date:  2009-09-01       Impact factor: 6.998

10.  Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.

Authors:  Shanmugapriya Thangavadivel; Qiuhong Zhao; Narendranath Epperla; Lindsey Rike; Xiaokui Mo; Mohamed Badawi; Darlene M Bystry; Mitch A Phelps; Leslie A Andritsos; Kerry A Rogers; Jeffrey Jones; Jennifer A Woyach; John C Byrd; Farrukh T Awan
Journal:  Clin Cancer Res       Date:  2020-09-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.